Neuroscience
From FierceBiotech
FDA panel backs new epilepsy drug from GSK, Valeant
August 12, 2010 — 7:41am ET
By John Carroll
Read the full article
- Fda: Pcns Drugs Advisory Committee Results For Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
From The New York Times: F.D.A. Sees Promise in Alzheimer’s Imaging Drug By THE ASSOCIATED PRESS Published: January 20, 2011 Filed at 5:40 p.m. ESTWASHINGTON (AP) — A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical...
- Fda Approves Multiple Sclerosis Drug, Ampyra (dalfampridine) Extended-release
From FierceBiotech: FDA approves Acorda's new MS drug January 22, 2010 — 4:49pm ET By John Carroll [snip] The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with...
- Merck's Cladribine And Multiple Sclerosis
From FierceBiotech: Merck KGaA pulls ahead in hot oral MS drug race By John Carroll September 11, 2009 — 8:22am ET Researchers for Merck KGaA say that new analysis of the late-stage data for their oral drug cladribine highlight the drug's potential...
- Modafinil, Adhd, And The Fda
From The Washington Post: Use of Drug to Treat ADHD in Children Opposed Associated Press Friday, March 24, 2006; Page A11 The narcolepsy drug modafinil should not be approved as a treatment for attention-deficit hyperactivity disorder in children until...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the AP, via the New York Times website: FDA Panel Supports MS Drug's Market Return By THE ASSOCIATED PRESS Published: March 8, 2006 Filed at 11:24 a.m. ET WASHINGTON (AP) -- A Food and Drug Administration panel said Wednesday the agency should...
Neuroscience
Potiga (ezogabine)
From FierceBiotech
FDA panel backs new epilepsy drug from GSK, Valeant
August 12, 2010 — 7:41am ET
By John Carroll
"GlaxoSmithKline and Valeant got a solid endorsement for their new epilepsy drug Potiga (ezogabine) from the FDA's panel of experts, putting them on track to a likely approval. The experts unanimously agreed that the drug would benefit epilepsy patients whose meds couldn't stop seizures. And they agreed that careful monitoring would flag patients who experience an inability to urinate while taking the drug."
Read the full article
- Fda: Pcns Drugs Advisory Committee Results For Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
From The New York Times: F.D.A. Sees Promise in Alzheimer’s Imaging Drug By THE ASSOCIATED PRESS Published: January 20, 2011 Filed at 5:40 p.m. ESTWASHINGTON (AP) — A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical...
- Fda Approves Multiple Sclerosis Drug, Ampyra (dalfampridine) Extended-release
From FierceBiotech: FDA approves Acorda's new MS drug January 22, 2010 — 4:49pm ET By John Carroll [snip] The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with...
- Merck's Cladribine And Multiple Sclerosis
From FierceBiotech: Merck KGaA pulls ahead in hot oral MS drug race By John Carroll September 11, 2009 — 8:22am ET Researchers for Merck KGaA say that new analysis of the late-stage data for their oral drug cladribine highlight the drug's potential...
- Modafinil, Adhd, And The Fda
From The Washington Post: Use of Drug to Treat ADHD in Children Opposed Associated Press Friday, March 24, 2006; Page A11 The narcolepsy drug modafinil should not be approved as a treatment for attention-deficit hyperactivity disorder in children until...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the AP, via the New York Times website: FDA Panel Supports MS Drug's Market Return By THE ASSOCIATED PRESS Published: March 8, 2006 Filed at 11:24 a.m. ET WASHINGTON (AP) -- A Food and Drug Administration panel said Wednesday the agency should...